

Haematologica
HAEMATOL/2018/189837
Version 3

Efficacy of bendamustine and rituximab as first salvage treatment in chronic lymphocytic leukemia and indirect comparison with ibrutinib: a GIMEMA, ERIC and UK CLL FORUM study

Antonio Cuneo, George Follows, Gian Matteo Rigolin, Alfonso Piciocchi, Alessandra Tedeschi, Livio Trentin, Angeles Medina Perez, Marta Coscia, Luca Laurenti, Gerardo Musuraca, Lucia Farina, Alfredo Rivas Delgado, Ester Maria Orlandi, Piero Galieni, Francesca Romana Mauro, Carlo Visco, Angela Amendola, Atto Billio, Roberto Marasca, Annalisa Chiarenza, Vittorio Meneghini, Fiorella Ilariucci, Monia Marchetti, Stefano Molica, Francesca Re, Gianluca Gaidano, Marcos Gonzalez, Francesco Forconi, Stefania Ciolli, Agostino Cortelezzi, Marco Montillo, Lukas Smolej, Anna Schuh, Toby A. Eyre, Ben Kennedy, Kris M. Bowles, Marco Vignetti, Javier de la Serna, Carol Moreno, Robin Foà, and Paolo Ghia

Disclosures: ACuneo received honoraria for advisory board and lecturing from Janssen, Gilead, Abbvie, Roche. GF received honoraria for consultancy and lecturing and non-financial support from Gilead, Janssen, Roche, Abbvie and Celgene. GMR received honoraria for advisory board from Celgene and Mundipharma,;for lecturing from Gilead; non-financial support from Janssen, Roche, Takeda and Mundipharma. AT received honoraria for advisory board from Janssen, Abbvie, Amgen. RM received research grant, personal fees and non-financial support from Janssen, personal fees and non-financial support from Gilead and personal fee from Abvie, oche, Shire, Pfizer. SM received honoraria for advisory board from Roche, Jansen, AbbVie and Gilead. FR received honoraria for advisory board from Gilead. GG received personal fees from Roche, Gilead and Abbvie, personal fees and non-financial support from Janssen, outside the submitted work. FF received honoraria for consultancy and lecturing, and non-financial support from Gilead, Janssen, Roche, Abbvie, Celgene and Novartis. MM received honoraria for advisory committee from AbbVie and Janssen: for consultancy and advisory committee from Gilead: for research funding from Roche/Genentech; and for consultancy from Novartis. AS received honoraria for consultancy and lecturing and non-financial support from Gilead, Janssen, Roche, Abbvie and Celgene. TAE received honoraria for Consultancy and lecturing from Gilead and Janssen. BK received honoraria for consultancy and lecturing and non-financial support from Gilead, Janssen, Roche and Abbvie. RF received honoraria for advisory boards and speaker bureau from Roche, Abbvie and Janssen, for advisory boards from Celgene, Ariad and Amgen, for speaker bureau from Gilead and Sandoz. PGhia received honoraria for advisory board and lecturing from Janssen, Gilead, Abbvie, Roche.

Contributions: ACuneo, GF, GMR, CM, RF, PGhia designed, coordinated the study, analyzed and interpreted the data and wrote the manuscript. AB, SC, AC, PG, LL, FRM, SM, MM, CM, GMR, LS, ACuneo wrote the protocol GF, GMR, AT, LT, AMP, MC, LL, GM, LF, JD, EMO, PG, FRM, CV, AA, AB, RM, AChiarenza, VM, FI, MM, SM, FR, GG, MG, FF, SC, AC, LS, AS, TAE, BK, KMB, JdlS, CM, PGhia enrolled the patients. JdlS is the Spanish National Coordinator. AP and MV contributed to the study management, analyzed the data and undertook the statistical analyses. All the authors critically reviewed the data and approved the final manuscript.